Anthrax in America 2001-2003JOSHI, Shivang G; CYMET, Holly Berkovits; KERKVLIET, Gary et al.Journal of the National Medical Association. 2004, Vol 96, Num 3, pp 344-350, issn 0027-9684, 7 p.Article

Poisoned food, Poisoned uniforms, and Anthrax: Or, how Guerillas die in warWHITE, Luise.Osiris (Philadelphia, PA). 2004, Vol 19, pp 220-233, issn 0369-7827, 14 p.Article

Statistical analysis of bacterial spore aerosols created by opening a spore containing anthrax letter in an officeKOURNIKAKIS, Bill; WALKER, Mike; HO, Jim et al.Journal of aerosol science. 2009, Vol 40, Num 6, pp 514-522, issn 0021-8502, 9 p.Article

Anthrax vaccination induced anti-lethal factor IgG: Fine specificity and neutralizing capacityCROWE, Sherry R; GARMAN, Lori; ENGLER, Renata J. M et al.Vaccine. 2011, Vol 29, Num 20, pp 3670-3678, issn 0264-410X, 9 p.Article

Estimating aerosol hazards from an anthrax letterHO, J; DUNCAN, S.Journal of aerosol science. 2005, Vol 36, Num 5-6, pp 701-719, issn 0021-8502, 19 p.Article

Anthrax: altbekannt und hochaktuell: Hautmilzbrand am Auge = Anthrax: an old disease becomes topical: cutaneous anthrax and the eyeKALPADAKIS, P; RUDOLPH, G; STEFANI, F. H et al.Der Ophthalmologe (Berlin. Print). 2003, Vol 100, Num 3, pp 216-221, issn 0941-293X, 6 p.Article

Proteolytic assay-based screening identifies a potent inhibitor of anthrax lethal factorPARK, Hae-Chul; SUNG, So-Ra; SU MIN LIM et al.Microbial pathogenesis. 2012, Vol 53, Num 2, pp 109-112, issn 0882-4010, 4 p.Article

Efficient methods for large-area surface sampling of sites contaminated with pathogenic microorganisms and other hazardous agents: current state, needs, and perspectivesEDMONDS, Jason M.Applied microbiology and biotechnology. 2009, Vol 84, Num 5, pp 811-816, issn 0175-7598, 6 p.Article

Immunogenicity of a subunit vaccine against Bacillus anthracisCHICHESTER, Jessica A; MUSIYCHUK, Konstantin; DE LA ROSA, Patricia et al.Vaccine. 2007, Vol 25, Num 16, pp 3111-3114, issn 0264-410X, 4 p.Conference Paper

An immuno-diffusion assay to assess the protective antigen content of anthrax vaccineADAMS, Trudy; OSBOM, Sancha; RIJPKEMA, Sjoerd et al.Vaccine. 2005, Vol 23, Num 36, pp 4517-4520, issn 0264-410X, 4 p.Article

Potentiation of an anthrax DNA vaccine with electroporationLUXEMBOURG, A; HANNAMAN, D; NOLAN, E et al.Vaccine. 2008, Vol 26, Num 40, pp 5216-5222, issn 0264-410X, 7 p.Conference Paper

Biological agents with potential for misuse: a historical perspective and defensive measuresBHALLA, Deepak K; WARHEIT, David B.Toxicology and applied pharmacology. 2004, Vol 199, Num 1, pp 71-84, issn 0041-008X, 14 p.Article

Risk analysis of an anthrax outbreak in cattle and humans of Sesheke district of Western ZambiaMWEEMBA MUNANG'ANDU, Hetron; BANDA, Fredrick; CHIKAMPA, Webster et al.Acta tropica. 2012, Vol 124, Num 2, pp 162-165, issn 0001-706X, 4 p.Article

Advances in the development of next-generation anthrax vaccinesFRIEDLANDER, Arthur M; LITTLE, Stephen F.Vaccine. Supplement. 2009, Vol 27, Num 4, issn 1359-5938, D28-D32Article

Evaluation of Bacillus anthracis extractable antigen for testing anthrax immunitySHLYAKHOV, E; SHOENFELD, Y; GILBURD, B et al.Clinical microbiology and infection. 2004, Vol 10, Num 5, pp 421-424, issn 1198-743X, 4 p.Article

The history of anthraxSTERNBACH, George.The Journal of emergency medicine. 2003, Vol 24, Num 4, pp 463-467, issn 0736-4679, 5 p.Article

Role of chondroitin sulfate C in the action of anthrax toxinHYUN CHAN AHN; NA YOUNG KIM; GYEUNG HAENG HUR et al.Toxicology (Amsterdam). 2012, Vol 297, Num 1-3, pp 10-16, issn 0300-483X, 7 p.Article

Identification of New Dominant-Negative Mutants of Anthrax Protective Antigen Using Directed EvolutionGAOBING WU; CHUNFANG FENG; SHA CAO et al.Applied biochemistry and biotechnology. 2012, Vol 168, Num 5, pp 1302-1310, issn 0273-2289, 9 p.Article

Risk of disability for US army personnel vaccinated against anthrax, 1998―2005SULSKY, Sandra I; LUIPPOLD, Rose S; GARMAN, Patrick et al.Vaccine. 2011, Vol 29, Num 35, pp 6035-6041, issn 0264-410X, 7 p.Article

An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individualsHEWETSON, John F; LITTLE, Stephen F; IVINS, Bruce E et al.Vaccine. 2008, Vol 26, Num 33, pp 4262-4266, issn 0264-410X, 5 p.Article

La maladie du charbon = AnthraxKRUG-MILON, M.Les Nouvelles dermatologiques. 1987, Vol 6, Num 4, pp 340-341, issn 0752-5370Article

Anthrax : the challenges for decontaminationSHARP, Richard J; ROBERTS, Allen G.Journal of chemical technology and biotechnology (1986). 2006, Vol 81, Num 10, pp 1612-1625, issn 0268-2575, 14 p.Article

LE CHARBON: MALADIE HISTORIQUE, OUBLIEE, MAIS TOUJOURS PRESENTE.JOUD R; GLENAT P; BERTRAND JL et al.1978; LYON MED.; FR.; DA. 1978; VOL. 239; NO 9; PP. 575-576Article

SURVIVAL OF A PATIENT WITH INTESTINAL ANTHRAX.NALIN DR; SULTANA B; SAHUNJA R et al.1977; AMER. J. MED.; U.S.A.; DA. 1977; VOL. 62; NO 1; PP. 130-132; BIBL. 5 REF.Article

A deterministic model of an anthrax epizootic: threshold resultsHAHN, B. D; FURNISS, P. R.Ecological modelling. 1983, Vol 20, Num 2-3, pp 233-241, issn 0304-3800Article